The ESMO Congress is one of the most important international conferences in the field of oncology. It serves as a platform for the exchange of the latest research results, groundbreaking treatment methods, and innovative technologies in the field of cancer medicine. The ESMO Congress is held annually and will take place for the first time in Berlin from October 17 to 21, 2025, at the Messe Berlin exhibition center.
As in previous years, IGES Pharma will be on site. Several experts from the athagoras network will also attend the ESMO Congress 2025. Since early 2025, IGES has been part of the athagoras group, an alliance of specialized consulting firms in the pharmaceutical, biotech, and medical technology sectors.
Between 25,000 and 30,000 participants from all over the world are expected to attend the ESMO Congress. This underscores the importance of the congress as a key event for clinicians, researchers, patient representatives, and experts from the pharmaceutical industry. It plays a vital role in shaping future clinical practice and setting research priorities.
The scientific program is multidisciplinary and covers a wide range of topics. These include the latest findings on the development, detection, and treatment of cancer. A special focus is on precision oncology, immunotherapy, and the role of artificial intelligence in cancer diagnosis and therapy.
For IGES Pharma, the congress is a central platform for deepening dialogue with partners from industry and science on all issues relating to evidence, market access, and the commercialization of innovative therapies in the field of oncology. This is because oncology has been a key research and consulting segment at IGES for decades, with a large number of projects implemented for innovative drug manufacturers.
IGES experts expect this area to remain highly dynamic in the future. Wioletta Kotowa, Head of HTA & Value Demonstration at IGES Pharma: "Significant innovations are not only being made in the treatment of widespread types of cancer such as breast, lung, and gastrointestinal cancer. Promising approaches are also emerging in interdisciplinary areas such as biomarker research, translational research, immunotherapy, and psychosocial aspects of cancer, which provide sustainable benefit to patients and offer real added value in terms of treatment. At the same time, it is becoming more challenging to demonstrate the benefits of these innovations to European cost bearers in the European countries. I am looking forward to gaining many new insights at this year's ESMO Congress and to engaging in dialogue with our partners from industry and research."
IGES Pharma provides tailored market access solutions for biopharmaceutical companies, from strategy development to full-service product launches across key European markets. IGES Pharma has offices in France, Germany, Italy, the Netherlands, Sweden, Switzerland, and Spain. Its headquarters are located in Berlin.
Only necessary cookies are used on our website. We also carry out anonymous visitor measurement using the Matomo tool. For this purpose, the log data of the web server and the shortened IP address are analysed. It is not possible to draw conclusions about your person. Information on the processing of your data on our website can be found in our privacy policy.
Contact